<unk>  (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals (acquired by Abbott in 2009) under the brand name Physiotens &<unk> on.
Moxonidine
Pramocaine
Carctol
Ibogaine
Bromelain 
Iontocaine
Tesofensine
Lofexidine